Prosecution Insights
Last updated: November 20, 2026

Sigilon Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Analysis

Sigilon Therapeutics Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 8 examiners and 6 art units, creating a broad prosecution footprint across the technology area.

LANKFORD JR, LEON B is the busiest examiner, with 1 pending matter. Because the listed examiner assignments are individually limited, portfolio management should prioritize consistent disclosure and claim strategy rather than relying on one examiner relationship.

The art-unit distribution means counsel may encounter different approaches to related technical subject matter. A centralized review of claim terminology, support, and amendment boundaries can reduce inconsistency across responses while preserving arguments suited to each record.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

8
Total Pending OAs
6
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (50%)
4
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (38%)
Double-patenting + other1 (12%)
Multi-statute (no §101)4 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LANKFORD JR, LEON B 1 70.1% +31.4%
LEE, HOI YAN NMN 1 38.5% +74.9%
NATARAJAN, MEERA 1 62.7% +17.8%
CANELLA, KAREN A 1 62.3% +32.8%
THUESON, HANNA MARIE 1 79.4% +26.1%
CHANDRAKUMAR, NIZAL S 1 72.6% +18.3%
WILSON, MICHAEL C 1 41.5% +17.8%
WEIDNER, ADAM M 1 63.8% +33.5%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17598154 COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY WILSON, MICHAEL C 215d overdue
18932580 IMPLANTABLE PARTICLES AND RELATED METHODS LANKFORD JR, LEON B —
18724813 MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF LEE, HOI YAN NMN —
18274123 COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES CANELLA, KAREN A —

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17598154 COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY WILSON, MICHAEL C 215d overdue
17784972 COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF CHANDRAKUMAR, NIZAL S 29d overdue
18932580 IMPLANTABLE PARTICLES AND RELATED METHODS LANKFORD JR, LEON B —
18724813 MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF LEE, HOI YAN NMN —
18705759 COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS NATARAJAN, MEERA —
18274123 COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES CANELLA, KAREN A —
18274134 BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS THUESON, HANNA MARIE —
16651892 METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS WEIDNER, ADAM M —

Top Art Units

Art UnitApps
1643 2
1638 2
1657 1
1693 1
1625 1
1675 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18932580 IMPLANTABLE PARTICLES AND RELATED METHODS LANKFORD JR, LEON B 1657 §103§112 Non-Final OA — Pending Oct 30, 2024
18724813 MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF LEE, HOI YAN NMN 1693 §103§112Other Non-Final OA — Pending Jun 27, 2024
18705759 COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS NATARAJAN, MEERA 1643 §103 Non-Final OA — Pending Apr 29, 2024
18274123 COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES CANELLA, KAREN A 1643 §103§112 Non-Final OA — Pending Jul 25, 2023
18274134 BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS THUESON, HANNA MARIE 1638 §103 Non-Final OA — Pending Jul 25, 2023
17784972 COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF CHANDRAKUMAR, NIZAL S 1625 §103DP Final Rejection 29d overdue Pending Jun 13, 2022
17598154 COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY WILSON, MICHAEL C 1638 §103§112 Non-Final OA 215d overdue Pending Sep 24, 2021
16651892 METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS WEIDNER, ADAM M 1675 §103Other Final Rejection — Pending Mar 27, 2020

Managing Sigilon Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Sigilon Therapeutics Inc. have?

Sigilon Therapeutics Inc. has 8 pending office actions as of November 2026, spread across 6 art units and 8 examiners.

Which USPTO examiner handles the most Sigilon Therapeutics Inc. applications?

Leon B Lankford Jr. has the most, with 1 of Sigilon Therapeutics Inc.'s pending office actions.

What technology area are Sigilon Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month